Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

Vistide available in U.S. as CMV treatment in AIDS patients

July 26, 1996

rBCG-V3JI: Ajinomoto's vector-based vaccine

July 26, 1996

Immunogenic oligomeric HIV-1 gp160 vaccine described

July 26, 1996

Rz9456: Potential hematopoietic stem cell therapy for AIDS

July 26, 1996

Cyanovirin-N selected for high priority development by the National Cancer Institute

July 26, 1996

CHAM3 induces clinical and biological improvement in HIV patients

July 26, 1996

ZY-1 demonstrates therapeutic promise in HIV patients

July 26, 1996

TAR-PAK-140: University of Alberta's anti-HIV vector

July 26, 1996

Mulsal N shows significant CD4 cell count increases in trial

July 26, 1996

Virulizin enters phase I/II for drug-resistant HIV-related Kaposi's sarcoma

July 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.